Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates
(NASDAQ:RVMD), Custom-built model will be trained using Revolution Medicines' proprietary data to discover novel drug candidates Iambic to receive up to $25 million through a combination of upfront and expected near-term performance-based milestone payments for services related to Revolution Medicines' access to Iambic's industry-leading NeuralPLexer model for protein structure prediction REDWOOD CITY, Calif. and SAN […]